1918-01-0

Upstream product

• 7499-08-3 3-chloro-2-methylbenzoic acid 

Downstream Products

• 1616289-31-6 ethyl 2-(bromomethyl)-3,6-dichloro-benzoate 
• 1616289-32-7 ethyl 3,6-dichloro-2-(cyanomethyl)benzoate 
• 1616289-34-9 5,8-dichloro-3,4-dihydroisoquinolin-1(2H)-one 
• 1616289-35-0 7-bromo-5,8-dichloro-3,4-dihydroisoquinolin-1(2H)-one 
• 1616287-82-1 5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one 
• 1616289-37-2 2-{[2-(benzyloxy)-4,6-dimethylpyridin-3-yl]methyl}-5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1616289-30-5 ethyl 3,6-dichloro-2-methyl-benzoate 

Relevant academic research and scientific papers

EZH2 Inhibitors

The present invention relates to compounds that inhibit EZH2 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS

This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

ARYL AND HETEROARYL FUSED LACTAMS

This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.